Avadel Pharmaceuticals (AVDL) Competitors $10.08 -0.23 (-2.23%) (As of 10:52 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AVDL vs. BHVN, APLS, IMVT, SRRK, RNA, OGN, PTCT, VRNA, RYTM, and MLTXShould you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Biohaven (BHVN), Apellis Pharmaceuticals (APLS), Immunovant (IMVT), Scholar Rock (SRRK), Avidity Biosciences (RNA), Organon & Co. (OGN), PTC Therapeutics (PTCT), Verona Pharma (VRNA), Rhythm Pharmaceuticals (RYTM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Avadel Pharmaceuticals vs. Biohaven Apellis Pharmaceuticals Immunovant Scholar Rock Avidity Biosciences Organon & Co. PTC Therapeutics Verona Pharma Rhythm Pharmaceuticals MoonLake Immunotherapeutics Avadel Pharmaceuticals (NASDAQ:AVDL) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation, institutional ownership and community ranking. Which has stronger valuation & earnings, AVDL or BHVN? Avadel Pharmaceuticals has higher earnings, but lower revenue than Biohaven. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvadel Pharmaceuticals$138.16M7.19-$160.28M-$0.79-13.05Biohaven$462.51M7.93-$408.17M-$9.35-3.88 Which has more volatility & risk, AVDL or BHVN? Avadel Pharmaceuticals has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Is AVDL or BHVN more profitable? Biohaven has a net margin of 0.00% compared to Avadel Pharmaceuticals' net margin of -52.53%. Avadel Pharmaceuticals' return on equity of -93.34% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets Avadel Pharmaceuticals-52.53% -93.34% -44.77% Biohaven N/A -225.12%-158.89% Does the media refer more to AVDL or BHVN? In the previous week, Biohaven had 10 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 17 mentions for Biohaven and 7 mentions for Avadel Pharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 1.27 beat Biohaven's score of 0.68 indicating that Avadel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avadel Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate AVDL or BHVN? Avadel Pharmaceuticals currently has a consensus target price of $24.43, suggesting a potential upside of 136.94%. Biohaven has a consensus target price of $63.00, suggesting a potential upside of 73.75%. Given Avadel Pharmaceuticals' higher possible upside, equities research analysts clearly believe Avadel Pharmaceuticals is more favorable than Biohaven.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Biohaven 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.07 Does the MarketBeat Community favor AVDL or BHVN? Biohaven received 59 more outperform votes than Avadel Pharmaceuticals when rated by MarketBeat users. Likewise, 67.17% of users gave Biohaven an outperform vote while only 66.02% of users gave Avadel Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAvadel PharmaceuticalsOutperform Votes34266.02% Underperform Votes17633.98% BiohavenOutperform Votes40167.17% Underperform Votes19632.83% Do institutionals & insiders have more ownership in AVDL or BHVN? 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 4.8% of Avadel Pharmaceuticals shares are owned by insiders. Comparatively, 16.0% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryBiohaven beats Avadel Pharmaceuticals on 12 of the 19 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get Avadel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVDL vs. The Competition Export to ExcelMetricAvadel PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$993.49M$6.57B$5.15B$9.08BDividend YieldN/A2.99%5.12%4.24%P/E Ratio-13.0510.5987.1117.17Price / Sales7.19196.061,116.56117.15Price / CashN/A57.1643.2337.85Price / Book10.525.094.794.78Net Income-$160.28M$151.83M$120.55M$225.60M7 Day Performance-0.77%-2.14%-1.92%-1.23%1 Month Performance-11.58%-4.56%13.67%0.46%1 Year Performance-25.29%8.87%28.47%15.24% Avadel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVDLAvadel Pharmaceuticals2.6974 of 5 stars$10.08-2.2%$24.43+142.3%-25.3%$971.33M$138.16M-12.76154Positive NewsBHVNBiohaven3.6227 of 5 stars$40.92+6.4%$63.00+54.0%-9.5%$4.14B$462.51M-4.11239APLSApellis Pharmaceuticals4.4999 of 5 stars$33.25+0.2%$49.94+50.2%-42.5%$4.14B$396.59M-16.35702Positive NewsIMVTImmunovant1.4579 of 5 stars$27.56+4.9%$47.89+73.8%-37.7%$4.05BN/A-11.84120SRRKScholar Rock3.9948 of 5 stars$43.01+2.5%$40.43-6.0%+138.8%$4.03B$33.19M-18.35140Positive NewsRNAAvidity Biosciences2.178 of 5 stars$33.62+3.5%$63.60+89.2%+245.3%$4.01B$10.12M-11.28190Analyst ForecastAnalyst RevisionOGNOrganon & Co.4.8153 of 5 stars$14.74-3.7%$21.33+44.7%+4.8%$3.80B$6.26B2.9110,000PTCTPTC Therapeutics3.801 of 5 stars$47.75+3.0%$54.08+13.3%+67.5%$3.68B$937.82M-7.811,410Positive NewsVRNAVerona Pharma0.8532 of 5 stars$43.28+4.5%$43.83+1.3%+139.3%$3.52B$460,000.00-21.5730RYTMRhythm Pharmaceuticals4.1038 of 5 stars$56.06+1.5%$63.70+13.6%+21.1%$3.45B$77.43M-12.76140Analyst ForecastPositive NewsMLTXMoonLake Immunotherapeutics1.6112 of 5 stars$52.66+2.6%$79.88+51.7%-13.3%$3.37BN/A-39.802 Related Companies and Tools Related Companies BHVN Competitors APLS Competitors IMVT Competitors SRRK Competitors RNA Competitors OGN Competitors PTCT Competitors VRNA Competitors RYTM Competitors MLTX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVDL) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avadel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
